氨溴索治疗新型冠状病毒肺炎的临床效果分析

Analysis of the clinical effect of ambroxol hydrochloride on the treatment of COVID-19

目的观察盐酸氨溴索治疗新型冠状病毒肺炎的临床疗效和安全性。方法选取2020年1-6月在石家庄市第五医院住院的68例新型冠状病毒肺炎患者,随机分为对照组和观察组,每组34例。观察组和对照组患者均给予α干扰素500万U,雾化,2次/d;阿比多尔0.2g,口服,3次/d,疗程10d。观察组患者在接受常规治疗的基础上予盐酸氨溴索葡萄糖注射液(30mg,2次/d,静脉滴注)治疗,疗程2周。比较两组患者临床疗效、血清炎性指标变化及药物不良反应发生率。结果观察组治疗总有效率(85.3%)显著高于对照组(70.6%),差异有统计学意义(P<0.05)。观察组临床症状改善时间、肺部影像学改善时间以及住院时间均短于对照组,但差异均无统计学意义(P>0.05)。观察组治疗后的降钙素原(PCT)和C反应蛋白(CRP)水平较治疗前均明显降低(P<0.05),白细胞计数和淋巴细胞计数较治疗前均明显升高(P<0.05);对照组治疗后CRP水平较治疗前明显降低(P<0.05),白细胞计数和淋巴细胞计数较治疗前均明显升高(P<0.05),但PCT水平治疗前、后无明显差异(P>0.05)。观察组和对照组患者治疗期间均无不良反应发生。结论新型冠状病毒肺炎患者应用盐酸氨溴索治疗有助于促进其临床症状缓解及肺部病灶吸收并可减低炎症反应。

Objective To observe the clinical efficacy and safety of ambroxol hydrochloride on the treatment of Coronavirus disease 2019(COVID-19).Method A total of 68 patients with COVID-19 hospitalized in the Fifth Hospital of Shijiazhuang from January to June 2020 were selected and divided into control group and observation group,with 34 cases in each group.Both observation group and control group were given interferon-α5 million U,atomized,twice a day;arbidol 0.2g,orally,3 times/d,for 10d.Observation group was treated with ambroxol hydrochloride glucose injection(30 mg,twice a day,iv drip)on the basis of conventional treatment for 2 weeks.The clinical efficacy,changes in serum inflammatory indexes and the incidence of adverse drug reactions were compared between the two groups.Result The total effective rate of observation group(85.3%)was significantly higher than that in the control group(70.6%)(P<0.05).The clinical symptoms improvement time,pulmonary imaging improvement time and hospitalization time in the observation group were shorter than those in the control group,but the differences were not statistically significant(P>0.05).The levels of serum PCT and CRP in the observation group were significantly lower after treatment than before(P<0.05),leukocyte count and lymphocyte count were significantly higher than those before treatment(P<0.05).In the control group the CRP level after treatment was significantly lower than that before treatment(P<0.05),the leukocyte count and lymphocyte count were significantly higher than those before treatment(P<0.05),but there was no significant difference in PCT level before and after treatment(P>0.05).There was no adverse reaction in the observation group and the control group during the treatment period.Conclusion Ambroxol hydrochloride treatment for COVID-19 patients can promote the remission of clinical symptoms and absorption of pulmonary lesions,and reduce inflammatory response,which is worthy of popularization and application.